Epigenetic therapy for solid tumors: from bench science to clinical trials
作者： Yen-Yi Juo , Xue-Jun Gong , Ankita Mishra , Xiao Cui , Stephen B Baylin
DOI: 10.2217/EPI.14.73
关键词:
摘要: The cancer epigenome is characterized by global DNA methylation and chromatin changes, such as the hypermethylation of specific CpG island promoters. Epigenetic agents like methyltransferase or histone deacetylase inhibitors induce phenotype changes reactivation epigenetically silenced tumor suppressor genes. Despite initial promise in hematologic malignancies, epigenetic have not shown significant efficacy monotherapy against solid tumors. Recent trials showed that exert favorable modifier effects when combined with chemotherapy, hormonal therapy, other agents. Due to novel nature their mechanism, it important reconsider optimal patient selection, drug regimen, study design, outcome measures pursuing future order discover full potential this new therapeutic modality.
elsevier.com
futuremedicine.com
sci-hub.se 参考文章(163)
Toshikazu Ushijima, Hideyuki Takeshima, Epigenetics as a novel therapeutic target of cancer Gan to kagaku ryoho. Cancer & chemotherapy. ,vol. 40, pp. 1429- ,(2013)
Jeggo Pa, Holliday R, Mechanisms for changing gene expression and their possible relationship to carcinogenesis. Cancer surveys. ,vol. 4, pp. 557- ,(1985)
Carine Robert, Feyruz V. Rassool, HDAC inhibitors: roles of DNA damage and repair. Advances in Cancer Research. ,vol. 116, pp. 87- 129 ,(2012) , 10.1016/B978-0-12-394387-3.00003-3
G. Schwartsmann, H. Schunemann, C.N.F. Gorini, A.F. Ferreira Filho, C. Garbino, G. Sabini, I. Muse, L DiLeone, D.R. Mans, A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer. Investigational New Drugs. ,vol. 18, pp. 83- 91 ,(2000) , 10.1023/A:1006388031954
Elizabeth E. Cameron, Kurtis E. Bachman, Sanna Myöhänen, James G. Herman, Stephen B. Baylin, Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer Nature Genetics. ,vol. 21, pp. 103- 107 ,(1999) , 10.1038/5047
Huili Li, Katherine B. Chiappinelli, Angela A. Guzzetta, Hariharan Easwaran, Ray-Whay Chiu Yen, Rajita Vatapalli, Michael J. Topper, Jianjun Luo, Roisin M. Connolly, Nilofer S. Azad, Vered Stearns, Drew M. Pardoll, Nancy Davidson, Peter A. Jones, Dennis J. Slamon, Stephen B. Baylin, Cynthia A. Zahnow, Nita Ahuja, Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget. ,vol. 5, pp. 587- 598 ,(2014) , 10.18632/ONCOTARGET.1782
Yelena Zabelena, Louise B. Grochow, Constance Griffin, Anita Hawkins, Carole B. Miller, George Dover, William D. Figg, Michael R. Grever, Ross C. Donehower, Kathleen Burks, Li Jun Weng, Suoping Zhai, Steven D. Gore, Impact of Prolonged Infusions of the Putative Differentiating Agent Sodium Phenylbutyrate on Myelodysplastic Syndromes and Acute Myeloid Leukemia Clinical Cancer Research. ,vol. 8, pp. 963- 970 ,(2002)
F Sorm, J Vesely, THE ACTIVITY OF A NEW ANTIMETABOLITE, 5-AZACYTIDINE, AGAINST LYMPHOID LEUKAEMIA IN AK MICE. Neoplasma. ,vol. 11, pp. 123- ,(1964)
Hisashi Tamaru, Eric U. Selker, A Histone H3 Methyltransferase Controls DNA Methylation in Neurospora Crassa Nature. ,vol. 414, pp. 277- 283 ,(2001) , 10.1038/35104508
J. Treisman, M. Herlyn, S. A. Rosenberg, B. Johnson, J. Weber, D. Samid, M. Salgaller, N. Lassam, Expression of the MAGE-1 Tumor Antigen Is Up-Regulated by the Demethylating Agent 5-Aza-2′-Deoxycytidine Cancer Research. ,vol. 54, pp. 1766- 1771 ,(1994)